Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NEO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNeoGenomics adds former Flatiron Health CEO Carolyn Starrett to Board
Filed June 25, 2026 · Period ending June 23, 2026 · ~1 min read
Key Changes
-
medium
Board expanded from nine to ten directors with appointment of Carolyn Starrett, former Flatiron Health CEO (2021-2025), effective June 23, 2026. She will serve until the 2027 annual meeting.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
medium
Starrett brings 25+ years in data and technology companies with deep expertise in AI and data insights for cancer care. She spent a decade at Flatiron Health in executive roles and served on Foundation Medicine's board (2021-2024).
Exhibit 99.1 view on EDGAR →
Summary
NeoGenomics expanded its Board of Directors from nine to ten members and appointed Carolyn Starrett, former CEO of Flatiron Health, effective June 23, 2026. Starrett led Flatiron Health as CEO and Board Director from April 2021 to September 2025 and brings over 25 years of experience in data and technology companies, with particular expertise in AI and real-world data analytics in oncology. She also served on Foundation Medicine's board from 2021 to 2024 and currently runs Starrett Advisory, a strategic consulting firm.
For retail investors, this is a routine governance matter with no immediate concerns. The appointment signals NeoGenomics is adding expertise in AI-driven cancer diagnostics and real-world data analytics, areas that align with the company's strategic focus on expanding its diagnostic portfolio. Starrett will receive standard independent director compensation and serve until the 2027 annual meeting.
Section-by-Section Diff
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Carolyn Starrett to its Board of Directors.
NeoGenomics added Carolyn Starrett to its Board of Directors. Starrett brings over 25 years of experience in data and technology companies with expertise in AI and data insights in cancer care. She most recently served as CEO of Flatiron Health from April 2021 to September 2025 and is currently President of Starrett Advisory, a strategic consulting firm.
Added in current filing · view on EDGAR →
Ms. Starrett brings over 25 years of commercial, product, and operations experience at data and technology companies and a deep understanding of AI and data insights in cancer care and research. She spent the last ten years from 2016 to 2026 at Flatiron Health serving in a variety of executive roles and ultimately leading the company as CEO and Board Director from April 2021 to September 2025.
Starrett's background includes a decade at Flatiron Health, where she served as CEO and Board Director for over four years. She also served as a Board Director at Foundation Medicine from 2021-2024 and held leadership roles at a predictive analytics company and Boston Consulting Group. Her expertise in real-world data, analytics, and AI in oncology aligns with NeoGenomics' strategic focus on expanding its diagnostic portfolio and leveraging AI for cancer care improvements.
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On June 23, 2026, the Board of Directors (the "Board") of NeoGenomics, Inc. (the "Company") increased the size of the Board from nine to ten directors and appointed Carolyn S. Starrett as a director to fill the newly created vacancy, effective immediately.
The company expanded its Board of Directors by one seat and immediately filled it with Carolyn S. Starrett. She will serve until the 2027 annual meeting and receive standard independent director compensation. Board expansions typically signal the company is adding expertise or preparing for growth initiatives.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 25, 2026 · How we verify